Christopher M Siracusa1, Jamie Ryan2, Lisa Burns3, Yu Wang4, Nanhua Zhang5, John P Clancy6, Dennis Drotar7. 1. Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center (CCHMC), 3333 Burnet Ave, Cincinnati, OH 45202, USA. Electronic address: christopher.siracusa@cchmc.org. 2. Division of Behavioral Medicine and Clinical Psychology, CCHMC, 3333 Burnet Ave, Cincinnati, OH 45202, USA. Electronic address: jamie.ryan@cchmc.org. 3. Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center (CCHMC), 3333 Burnet Ave, Cincinnati, OH 45202, USA. Electronic address: lisa.burns2@cchmc.org. 4. Division of Biostatistics and Epidemiology, CCHMC, 3333 Burnet Ave, Cincinnati, OH 45202, USA. Electronic address: yu.wang@cchmc.org. 5. Division of Biostatistics and Epidemiology, CCHMC, 3333 Burnet Ave, Cincinnati, OH 45202, USA. Electronic address: nanhua.zhang@cchmc.org. 6. Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center (CCHMC), 3333 Burnet Ave, Cincinnati, OH 45202, USA. Electronic address: john.clancy@cchmc.org. 7. Division of Behavioral Medicine and Clinical Psychology, CCHMC, 3333 Burnet Ave, Cincinnati, OH 45202, USA. Electronic address: dennis.drotar@cchmc.org.
Abstract
BACKGROUND: Previous studies of CF treatments have shown suboptimal adherence, though little has been reported regarding adherence patterns to ivacaftor. Electronic monitoring (EM) of adherence is considered a gold standard of measurement. METHODS: Adherence rates by EM were prospectively obtained and patterns over time were analyzed. EM-derived adherence rates were compared to pharmacy refill history and self-report. RESULTS: 12 subjects (age 6-48 years; CFTR-G551D mutation) previously prescribed ivacaftor were monitored for a mean of 118 days. Overall adherence by EM was 61% (SD=28%) and decreased over time. Median duration between doses was 16.9 hours (IQR 13.9-24.1 hours) and increased over time. There was no correlation between EM-derived adherence and either refill history (84%, r=0.26, p=0.42) or self-report (100%, r=0.40, p=0.22). CONCLUSIONS: Despite the promising nature of ivacaftor, our data suggest adherence rates are suboptimal and comparable to other prescribed CF therapies, and more commonly used assessments of adherence may be unreliable.
BACKGROUND: Previous studies of CF treatments have shown suboptimal adherence, though little has been reported regarding adherence patterns to ivacaftor. Electronic monitoring (EM) of adherence is considered a gold standard of measurement. METHODS: Adherence rates by EM were prospectively obtained and patterns over time were analyzed. EM-derived adherence rates were compared to pharmacy refill history and self-report. RESULTS: 12 subjects (age 6-48 years; CFTR-G551D mutation) previously prescribed ivacaftor were monitored for a mean of 118 days. Overall adherence by EM was 61% (SD=28%) and decreased over time. Median duration between doses was 16.9 hours (IQR 13.9-24.1 hours) and increased over time. There was no correlation between EM-derived adherence and either refill history (84%, r=0.26, p=0.42) or self-report (100%, r=0.40, p=0.22). CONCLUSIONS: Despite the promising nature of ivacaftor, our data suggest adherence rates are suboptimal and comparable to other prescribed CF therapies, and more commonly used assessments of adherence may be unreliable.
Authors: Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245
Authors: Sonya L Heltshe; Nicole Mayer-Hamblett; Jane L Burns; Umer Khan; Arthur Baines; Bonnie W Ramsey; Steven M Rowe Journal: Clin Infect Dis Date: 2014-11-25 Impact factor: 9.079
Authors: Avani C Modi; Crystal S Lim; Nami Yu; David Geller; Mary H Wagner; Alexandra L Quittner Journal: J Cyst Fibros Date: 2006-05-05 Impact factor: 5.482
Authors: Frank J Accurso; Steven M Rowe; J P Clancy; Michael P Boyle; Jordan M Dunitz; Peter R Durie; Scott D Sagel; Douglas B Hornick; Michael W Konstan; Scott H Donaldson; Richard B Moss; Joseph M Pilewski; Ronald C Rubenstein; Ahmet Z Uluer; Moira L Aitken; Steven D Freedman; Lynn M Rose; Nicole Mayer-Hamblett; Qunming Dong; Jiuhong Zha; Anne J Stone; Eric R Olson; Claudia L Ordoñez; Preston W Campbell; Melissa A Ashlock; Bonnie W Ramsey Journal: N Engl J Med Date: 2010-11-18 Impact factor: 176.079
Authors: John E Pascoe; Hemant Sawnani; Oscar H Mayer; Keith McConnell; Joseph M McDonough; Cynthia White; Anne M Rutkowski; Raouf S Amin; Avani C Modi Journal: Pediatr Pulmonol Date: 2016-11-22
Authors: Katherine B Hisert; Sonya L Heltshe; Christopher Pope; Peter Jorth; Xia Wu; Rachael M Edwards; Matthew Radey; Frank J Accurso; Daniel J Wolter; Gordon Cooke; Ryan J Adam; Suzanne Carter; Brenda Grogan; Janice L Launspach; Seamas C Donnelly; Charles G Gallagher; James E Bruce; David A Stoltz; Michael J Welsh; Lucas R Hoffman; Edward F McKone; Pradeep K Singh Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405
Authors: Rhonda D Szczesniak; Teresa Pestian; Leo L Duan; Dan Li; Sophia Stamper; Brycen Ferrara; Elizabeth Kramer; John P Clancy; Daniel Grossoehme Journal: BMC Pulm Med Date: 2020-06-18 Impact factor: 3.317